Research Article

H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer

Figure 3

Sequential administration of BC-819 and gemcitabine in a subcutaneous human pancreatic tumor in nude mouse model. and Confluent CRL-1469 human pancreatic carcinoma cells were injected subcutaneously into the back of athymic nude mice. After tumor development (30 days), three BC-819 administrations were performed, with a 2-day interval between each treatment, by direct injection into the tumor at days 0, 2, and 4. Mice were randomly divided into one of the following groups: control (glucose 5%), BC-819 alone, gemcitabine alone and BC-819 + gemcitabine. Average tumor growth progression of control ( 𝑁 = 7 ), BC-819 ( 𝑁 = 7 ), gemcitabine ( 𝑁 = 7 ), and BC-819 + gemcitabine ( 𝑁 = 7 ) groups comparing the tumor volume measured at the end of the experiment to the volume measured at the beginning.
351750.fig.003